Menu

Regulators OK Clinical Trials Using Donor Stem Cells

Japanese health officials approve human experiments to treat macular degeneration with a cell therapy derived from induced pluripotent stem cells.

Feb 6, 2017
Kerry Grens

WIKIPEDIA, TMHLEE

Update (March 28): Today, doctors administered the first donor-derived iPSC transplant that Takahashi developed, Nature News reported. A man in his 60s received the therapy, aimed at treating macular degeneration. Earlier this year, Takahashi's team reported success using a patient's own iPSCs that were reprogrammed into retinal cells.

Researchers in Japan who have been developing a cell therapy for macular degeneration received support from health authorities this week (February 1) to begin a clinical trial using donor-derived induced pluripotent stem cells (IPSCs) converted to retinal cells. This will be the first trial in which the team’s physicians administer donor cells, an approach expected to lower costs and preparation time.

Previously, this same group of scientists, led by the Riken Center for Developmental Biology’s Masayo Takahashi, tested an iPSC-based therapy for macular degeneration using the patients’ own cells.

“The procedure was expensive and time-consuming, costing about 100 million yen ($930,000) to cultivate and test the iPS cells and about 11 months for the transplant to take place,” The Asahi Shinbum reported in June 2016. “But with the use of the iPS cell stock [from donors], the time frame could be reduced to as short as a month and costs could be significantly reduced.”

In September, Takahashi and her colleagues reported that iPSC-derived retinal pigment epithelial (RPE) cells from monkeys implanted in immune-matched monkeys’ eyes were not rejected. And in a second paper published simultaneously, they demonstrated that human-donor RPE cells made from iPSCs did not spark an immune response from lymphocytes in culture.

“The papers together make a strong case that allogeneic iPSC-derived RPE cells can effectively be used for transplantation into immune matched recipients without eliciting a major immune response,” stem cell biologist Paul Knoepfler of the University of California, Davis, told The Scientist at the time. “What this means is that iPSC-based treatments for macular degeneration, for instance, likely will not have to rely on autologous transplants if matching is done.”

Nikkei Asian Review reported that about five patients will enter the donor-cell trial, which is slated to begin in the first half of 2017.

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.